BEIJING, Dec. 18, 2025 /PRNewswire/ -- Syneron Bio, an macrocyclic peptide drug discovery company driven by intelligent high-throughput platform, has successfully completed its Series A and A+ financing rounds, raising close to USD 100 million in total. Top-tier investors participated in the round, including AstraZeneca, AZ-CICC Healthcare Investment Fund, Pfizer Biotech Development Investment Fund, GL Ventures, 5Y Capital, Sinovation Capital, Lenovo Capital, Gree Capital and KHK fund. Dr. Xiao

Eli Lilly has announced new study data on Inluriyo (imlunestrant) as a treatment for patients with ER+, HER2– metastatic breast cancer. It applies specifically to advanced or metastatic breast cancer that is oestrogen receptor positive (ER+), human epidermal growth factor receptor 2-negative (HER2–), where the disease has progressed on a prior aromatase inhibitor (AI), with or without a cyclin-dependent kinase 4/6 inhibitor. Follow-up results from the phase 3 EMBER-3 study showed that, as a mono

Researchers from The Institute of Cancer Research, London, will contribute to a £13.7 million research consortium aimed at developing new brain tumour treatments, following an announcement by the NIHR today. The funding will establish the NIHR Brain Tumour Research Consortium. The consortium is a national partnership uniting hospitals, universities, cancer centres and charities along with patients. This is a coordinated UK-wide effort to transform outcomes for people living with brain tumours an

iStock, Suchat longthara The fatalities were attributed to interstitial lung disease, a known side effect of Daiichi Sankyo’s DXd-based antibody-drug conjugates. A spokesperson declined to say how many patients died. The FDA has placed a partial clinical hold on Merck and Daiichi Sankyo’s late-stage development program for their antibody-drug conjugate ifinatamab deruxtecan after “a higher than expected” number of deaths were detected, according to several media reports on Thursday. The compa

Agreement addresses all requests by President Trump to reduce drug costs in the U.S., encourage global investment and protect American biopharma leadership Company reinforces commitment to U.S. manufacturing and American jobs FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced an agreement with the U.S. government designed to reduce drug costs for Americans, reinforcing the company’s long-standing commitment to U.S.-based innovation, affordability, and glo

Researchers have revealed that so-called “junk DNA” contains powerful switches that help control brain cells linked to Alzheimer’s disease. By experimentally testing nearly 1,000 DNA switches in human astrocytes, scientists identified around 150 that truly influence gene activity—many tied to known Alzheimer’s risk genes. The findings help explain why many disease-linked genetic changes sit outside genes themselves. The resulting dataset is now being used to train AI systems to predict gene cont

FOSTER CITY, Calif.--(BUSINESS WIRE)-- Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced that it has entered into a subscription agreement with entities associated with TCGX, an institutional investor, for a private placement of 1,000,000 shares of its common stock (the “Common Stock”). The Common Stock issued to the private placement investors at closing will be priced at $68.48 per share for approximately $68.5 million in gross proceeds. The proceeds f

MYQORZO, a Cardiac Myosin Inhibitor, Directly Addresses Underlying Hypercontractility Associated with Obstructive HCM FDA Approval Based on Results of SEQUOIA-HCM MYQORZO is Company’s First FDA-Approved Medicine Company to Host Investor Conference Call Today at 4:30 PM Eastern Time SOUTH SAN FRANCISCO, Calif., Dec. 19, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the U.S. Food and Drug Administration (FDA) has approved MYQORZO™ (aficamten), 5 mg, 10 mg,

iStock, Sundry Photography BioMarin Pharmaceutical has faced a rocky road, promising and then backing off revenue targets and cutting assets that have underperformed. But Amicus’ rare disease portfolio is already bringing in $600 million annually. BioMarin Pharmaceutical is purchasing Amicus Therapeutics in an all-cash deal worth $4.8 billion, in a bid to pump up its rare disease portfolio after a series of cuts. The deal prices shares of the New Jersey–based Amicus at $14.50, a 33% premium on

– Bempedoic Acid Highlighted by ACC for LDL-C Lowering in Patients with Peripheral Artery Disease and Diabetes Based on Proven Cardiovascular and Limb Benefits – ANN ARBOR, Mich., Dec. 19, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) welcomed the inclusion of bempedoic acid as a first-line, evidence-based therapy for LDL-C lowering for patients on maximally tolerated statins in the 2025 American College of Cardiology (ACC) Scientific Statement on Management of Peripheral Artery Disease (PAD)